Events
-
-
-
-
ENDO 2026: Women’s thyroid cancer risk may be linked to reproductive lifespan and hormone therapy
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
Mapping cancer’s weak spots reveals new precision targets for breast cancer
Understanding why cancer cells rely on specific genes is critical for designing effective targeted therapies.…
Seeing thyroid cancer in a new light: when AI meets label-free imaging in the operating room
Thyroid cancer is the most common endocrine cancer, affecting more people each year as detection…
Survival outcomes in young adults with metastatic colorectal cancer vary by socioeconomic context
A large cohort study published in JAMA Network Open has documented significant disparities in survival…
SABCS 2025: Adding tucatinib to first-line maintenance therapy delayed disease progression in HER2-positive metastatic breast cancer in HER2CLIMB-05 trial
- SABCS 2025: A multimodal AI model may improve recurrence risk stratification in early breast cancer
- SABCS 2025: Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for certain endocrine therapy-refractory advanced breast cancers
- SABCS 2025: Menopausal hormone therapy may not pose breast cancer risk for women with BRCA mutations
Episode 4: Ian Olver’s Journeys in Supportive Care
Welcome to the fourth episode of Supportive Care Matters, a podcast Hosted by Medical Oncologist Professor Bogda Koczwara AM from…
ASCO GU 2024: Study shows positive results for patients with muscle-invasive urothelial carcinoma
- ASCO GU 2024: Subcutaneous nivolumab as effective as IV for renal cell carcinoma with much faster treatment time
- ASCO GU 2024: Combination of cabozantinib and atezolizumab offers hope for patients with type of advanced prostate cancer with poor prognosis
- Prostate cancer: Newly-developed inhibitor shows massive potential
Could a single drug treat the two leading causes of death in the US: cancer and cardiovascular disease?
Bryan Smith, Michigan State University What would you guess are the two biggest killers in the world? Based on media…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.